Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of
everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer.
For the 2-drug sequence, participants will receive 1 of these drugs and may start taking
another of these drugs after that. Researchers will also study the safety of these 2-drug
sequences.